← Leaderboards

Robert H Vonderheide

University Of Pennsylvania

Google Scholar ↗PubMed ↗ORCID ↗

$28,425,019

Attributed

$31,784,069

Total exposure

20

Grants

19

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $16M · FY2005–25

$20M$15M$10M$5M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$124,683,513 · 22

By mechanism

P30$96,387,344 · 11

P01$15,135,034 · 4

R01$10,572,198 · 4

P50$1,936,752 · 2

K08$652,185 · 1

Top collaborators

Ben Z Stanger11 shared
Amit Maity5 shared
Andy J Minn5 shared
E. John Wherry5 shared

Most similar at University Of Pennsylvania

Same institution · by research overlap

Warren S Pear$28,448,095
Amy Cleveland Durham$1,066,215
Constantinos Koumenis$17,144,115
Xiaowei Xu$9,845,570
Gyungah Jun$5,317,894

Others in their field

Top investigators on “Malignant Neoplasms”

David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
Richard K. Wilson · Washington University$274,272,747
Larry Arthur$223,443,122
Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879

Research focus

Malignant NeoplasmsProgramsImmunotherapyTumorFosteringCancer Center Support GrantMemberResourcesCancer CenterClinical ResearchResearch PersonnelInnovationClinical TrialsGeneticBasic ScienceFundingT-LymphocytePopulation SciencesLeadershipCancer ControlMelanomaImmuneGrantCatchment Area

Grant awards (127)

Abramson Cancer Center Support Grant$9,300,603

P30 · FY2025 · CA · contact PI

Leadership, Planning and Evaluation$844,827

P30 · FY2025 · CA · contact PI

Abramson Cancer Center Support Grant$203,125

P30 · FY2025 · CA · contact PI

Abramson Cancer Center Support Grant$9,230,603

P30 · FY2024 · CA · contact PI

Leadership, Planning and Evaluation$840,257

P30 · FY2024 · CA · contact PI

Abramson Cancer Center Support Grant$203,125

P30 · FY2024 · CA · contact PI

Abramson Cancer Center Support Grant$9,040,646

P30 · FY2023 · CA · contact PI

Developmental Funds$1,431,350

P30 · FY2023 · CA · contact PI

Leadership, Planning and Evaluation$832,231

P30 · FY2023 · CA · contact PI

Abramson Cancer Center Support Grant$500,000

P30 · FY2023 · CA · contact PI

Abramson Cancer Center Support Grant$299,940

P30 · FY2023 · CA · contact PI

Abramson Cancer Center Support Grant$158,306

P30 · FY2023 · CA · contact PI

Biostatistics and Bioinformatics Core$1

P30 · FY2023 · CA · contact PI

Abramson Cancer Center Support Grant$8,871,602

P30 · FY2022 · CA · contact PI

Radiation and checkpoint blockade for cancer immune therapy$2,263,439

P01 · FY2022 · CA · contact PI

Developmental Funds$1,384,389

P30 · FY2022 · CA · contact PI

Leadership, Planning and Evaluation$822,283

P30 · FY2022 · CA · contact PI

Molecular Determinants and Therapeutic Consequences of Immune Heterogeneity in Cancer$644,986

R01 · FY2022 · CA · contact PI

Project 1: Clinical and immune impact of radiation and dual checkpoint blockade in patients$639,331

P01 · FY2022 · CA · contact PI

Abramson Cancer Center Support Grant$115,000

P30 · FY2022 · CA · contact PI

Core A: Administration$67,675

P01 · FY2022 · CA · contact PI

Abramson Cancer Center Support Grant$45,156

P30 · FY2022 · CA · contact PI

Abramson Cancer Center Support Grant$45,139

P30 · FY2022 · CA · contact PI

Program Integration$16,350

P01 · FY2022 · CA · contact PI

Biostatistics and Bioinformatics Core$2,137

P30 · FY2022 · CA · contact PI

Abramson Cancer Center Support Grant$8,720,099

P30 · FY2021 · CA · contact PI

Radiation and checkpoint blockade for cancer immune therapy$2,275,599

P01 · FY2021 · CA · contact PI

Developmental Funds$1,349,148

P30 · FY2021 · CA · contact PI

Leadership, Planning and Evaluation$830,100

P30 · FY2021 · CA · contact PI

Molecular Determinants and Therapeutic Consequences of Immune Heterogeneity in Cancer$657,258

R01 · FY2021 · CA · contact PI

Project 1: Clinical and immune impact of radiation and dual checkpoint blockade in patients$646,146

P01 · FY2021 · CA · contact PI

Abramson Cancer Center Support Grant$367,625

P30 · FY2021 · CA · contact PI

Abramson Cancer Center Support Grant$200,000

P30 · FY2021 · CA · contact PI

Abramson Cancer Center Support Grant$199,375

P30 · FY2021 · CA · contact PI

Abramson Cancer Center Support Grant.$162,500

P30 · FY2021 · CA · contact PI

Molecular Determinants and Therapeutic Consequences of Immune Heterogeneity in Cancer$162,333

R01 · FY2021 · CA · contact PI

Abramson Cancer Center Support Grant$124,614

P30 · FY2021 · CA · contact PI

Abramson Cancer Center Support Grant$124,550

P30 · FY2021 · CA · contact PI

Abramson Cancer Center Support Grant$115,000

P30 · FY2021 · CA · contact PI

Core A: Administration$67,675

P01 · FY2021 · CA · contact PI

Program Integration$16,350

P01 · FY2021 · CA · contact PI

Abramson Cancer Center Support Grant$7,830,372

P30 · FY2020 · CA · contact PI

ADMINISTRATION (Admin Core)$1,561,612

P30 · FY2020 · CA · contact PI

DEVELOPMENTAL FUNDS (Core 002)$1,058,962

P30 · FY2020 · CA · contact PI

Molecular Determinants and Therapeutic Consequences of Immune Heterogeneity in Cancer$820,052

R01 · FY2020 · CA · contact PI

Abramson Cancer Center Support Grant$500,018

P30 · FY2020 · CA · contact PI

Abramson Cancer Center Support Grant$299,999

P30 · FY2020 · CA · contact PI

Abramson Cancer Center Support Grant$199,938

P30 · FY2020 · CA · contact PI

ADMINISTRATION (Admin Core)$199,938

P30 · FY2020 · CA · contact PI

Abramson Cancer Center Support Grant$150,078

P30 · FY2020 · CA · contact PI

Abramson Cancer Center Support Grant$86,251

P30 · FY2020 · CA · contact PI

non-AIDS defining cancers (NADCs) among aging HIV+ individuals$79,341

P30 · FY2020 · CA · contact PI

Abramson Cancer Center Support Grant$79,341

P30 · FY2020 · CA · contact PI

Immunotherapy and Tumor Microenvironment in HIV/AIDS Cancer Patients$73,383

P30 · FY2020 · CA · contact PI

Abramson Cancer Center Support Grant$73,383

P30 · FY2020 · CA · contact PI

PLANNING AND EVALUATION (Core 001)$56,074

P30 · FY2020 · CA · contact PI

Abramson Cancer Center Support Grant$7,771,686

P30 · FY2019 · CA · contact PI

Radiation and checkpoint blockade for cancer immune therapy$2,286,184

P01 · FY2019 · CA · contact PI

ADMINISTRATION (Admin Core)$1,563,098

P30 · FY2019 · CA · contact PI

DEVELOPMENTAL FUNDS (Core 002)$1,059,970

P30 · FY2019 · CA · contact PI

Project 1: Clinical and immune impact of radiation and dual checkpoint blockade in patients$654,058

P01 · FY2019 · CA · contact PI

Molecular Determinants and Therapeutic Consequences of Immune Heterogeneity in Cancer$640,513

R01 · FY2019 · CA · contact PI

Abramson Cancer Center Support Grant$187,502

P30 · FY2019 · CA · contact PI

Abramson Cancer Center Support Grant$149,953

P30 · FY2019 · CA · contact PI

Abramson Cancer Center Support Grant$94,283

P30 · FY2019 · CA · contact PI

Core A: Administration$67,674

P01 · FY2019 · CA · contact PI

PLANNING AND EVALUATION (Core 001)$56,127

P30 · FY2019 · CA · contact PI

Abramson Cancer Center Support Grant$28,749

P30 · FY2019 · CA · contact PI

Program Integration$16,350

P01 · FY2019 · CA · contact PI

Immunobiology Research Program$7,211

P30 · FY2019 · CA · contact PI

Immunobiology Research Program$5,768

P30 · FY2019 · CA · contact PI

Immunobiology Research Program$3,626

P30 · FY2019 · CA · contact PI

Immunobiology Research Program$1,106

P30 · FY2019 · CA · contact PI

Abramson Cancer Center Support Grant$7,716,753

P30 · FY2018 · CA · contact PI

Radiation and checkpoint blockade for cancer immune therapy$2,311,469

P01 · FY2018 · CA · contact PI

DEVELOPMENTAL FUNDS (Core 002)$730,844

P30 · FY2018 · CA · contact PI

Molecular Determinants and Therapeutic Consequences of Immune Heterogeneity in Cancer$662,729

R01 · FY2018 · CA · contact PI

Project 1: Clinical and immune impact of radiation and dual checkpoint blockade in patients$654,726

P01 · FY2018 · CA · contact PI

Engineered T Cell Therapy for Melanoma$285,642

P50 · FY2018 · CA · contact PI

Abramson Cancer Center Support Grant$244,519

P30 · FY2018 · CA · contact PI

Developmental Research Program$87,259

P50 · FY2018 · CA · contact PI

Core A: Administration$67,674

P01 · FY2018 · CA · contact PI

Abramson Cancer Center Support Grant$65,235

P30 · FY2018 · CA · contact PI

Abramson Cancer Center Support Grant$55,717

P30 · FY2018 · CA · contact PI

Program Integration$16,350

P01 · FY2018 · CA · contact PI

Immunobiology Research Program$9,404

P30 · FY2018 · CA · contact PI

DEVELOPMENTAL FUNDS (Core 002)$2,508

P30 · FY2018 · CA · contact PI

DEVELOPMENTAL FUNDS (Core 002)$2,143

P30 · FY2018 · CA · contact PI

Abramson Cancer Center Support Grant$7,810,244

P30 · FY2017 · CA · contact PI

Radiation and checkpoint blockade for cancer immune therapy$2,329,233

P01 · FY2017 · CA · contact PI

Project 1: Clinical and immune impact of radiation and dual checkpoint blockade in patients$654,726

P01 · FY2017 · CA · contact PI

Engineered T Cell Therapy for Melanoma$320,120

P50 · FY2017 · CA · contact PI

Developmental Research Program$85,150

P50 · FY2017 · CA · contact PI

Immunobiology Research Program$73,099

P30 · FY2017 · CA · contact PI

Core A: Administration$67,675

P01 · FY2017 · CA · contact PI

Abramson Cancer Center Support Grant$62,491

P30 · FY2017 · CA · contact PI

Program Integration$16,350

P01 · FY2017 · CA · contact PI

Immunobiology and immunotherapy of pancreatic cancer$681,452

R01 · FY2016 · CA · contact PI

Engineered T Cell Therapy for Melanoma$339,874

P50 · FY2016 · CA · contact PI

Immunobiology Research Program$72,887

P30 · FY2016 · CA · contact PI

Developmental Research Program$68,884

P50 · FY2016 · CA · contact PI

Immunobiology and immunotherapy of pancreatic cancer$635,533

R01 · FY2015 · CA · contact PI

Combined CD40 activation and CTLA4 blockade in melanoma$332,000

R01 · FY2015 · CA · contact PI

Engineered T Cell Therapy for Melanoma$300,231

P50 · FY2015 · CA · contact PI

Developmental Research Program$79,859

P50 · FY2015 · CA · contact PI

Immunobiology and immunotherapy of pancreatic cancer$604,414

R01 · FY2014 · CA · contact PI

Combined CD40 activation and CTLA4 blockade in melanoma$322,040

R01 · FY2014 · CA · contact PI

Engineered T Cell Therapy for Melanoma$296,514

P50 · FY2014 · CA · contact PI

Developmental Research Program$73,219

P50 · FY2014 · CA · contact PI

Immunobiology and immunotherapy of pancreatic cancer$585,722

R01 · FY2013 · CA · contact PI

Combined CD40 activation and CTLA4 blockade in melanoma$312,080

R01 · FY2013 · CA · contact PI

Immunobiology and immunotherapy of pancreatic cancer$623,108

R01 · FY2012 · CA · contact PI

Combined CD40 activation and CTLA4 blockade in melanoma$332,000

R01 · FY2012 · CA · contact PI

Immunoregulation and immunotherapy of breast cancer$307,381

R01 · FY2012 · CA · contact PI

Combined CD40 activation and CTLA4 blockade in melanoma$332,000

R01 · FY2011 · CA · contact PI

Immunoregulation and immunotherapy of breast cancer$310,394

R01 · FY2011 · CA · contact PI

Immunoregulation and immunotherapy of breast cancer$329,594

R01 · FY2010 · CA · contact PI

Immunoregulation and immunotherapy of breast cancer$327,534

R01 · FY2009 · CA · contact PI

Immunoregulation and immunotherapy of breast cancer$316,994

R01 · FY2007 · CA · contact PI

Immunoregulation and immunotherapy of breast cancer$316,954

R01 · FY2006 · CA · contact PI

Immunoregulation and immunotherapy of breast cancer$315,127

R01 · FY2005 · CA

TELOMERASE AS A WIDELY EXPRESSED TUMOR ANTIGEN$130,437

K08 · FY2004 · CA

TELOMERASE AS A WIDELY EXPRESSED TUMOR ANTIGEN$130,437

K08 · FY2003 · CA

TELOMERASE AS A WIDELY EXPRESSED TUMOR ANTIGEN$130,437

K08 · FY2002 · CA

TELOMERASE AS A WIDELY EXPRESSED TUMOR ANTIGEN$73,119

K08 · FY2001 · CA

TELOMERASE AS A WIDELY EXPRESSED TUMOR ANTIGEN$57,318

K08 · FY2001 · CA

TELOMERASE AS A WIDELY EXPRESSED TUMOR ANTIGEN$130,437

K08 · FY2000 · CA